AVEO Stock Hits New 52-Week Low (AVEO)

NEW YORK ( TheStreet) -- AVEO Pharmaceuticals (Nasdaq: AVEO) hit a new 52-week low Wednesday as it is currently trading at $11.22, below its previous 52-week low of $11.28 with 36,912 shares traded as of 10:10 a.m. ET. Average volume has been 272,200 shares over the past 30 days.

AVEO has a market cap of $534.4 million and is part of the health care sector and drugs industry. Shares are down 28.7% year to date as of the close of trading on Tuesday.

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of cancer therapeutics. The company has a P/E ratio of 16.8, above the average drugs industry P/E ratio of 16.6 and below the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates AVEO as a sell. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. You can view the full AVEO Ratings Report.

See all 52-week low stocks or get investment ideas from our investment research center.
null

If you liked this article you might like

Biotech Names Flexing Their Muscles

Biotech Names Flexing Their Muscles

How I've Prepared for Hurricane Irma -- and a Market Pullback

How I've Prepared for Hurricane Irma -- and a Market Pullback

How I'm Prepared for Irma -- and a Pullback

How I'm Prepared for Irma -- and a Pullback

AVEO Pharmaceuticals (AVEO) Stock Pops on European Licensing Agreement

AVEO Pharmaceuticals (AVEO) Stock Pops on European Licensing Agreement

When Eyeing Small Biotechs, Partnerships Are Huge

When Eyeing Small Biotechs, Partnerships Are Huge